Travoprost - A new prostaglandin analogue for the treatment of glaucoma

Expert Opinion on Pharmacotherapy

Volumn 3, Issue 7, 2002, Pages 965-977

  Whitson, Jess T ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

FP prostanoid receptor; Glaucoma; Intraocular pressure; Latanoprost; Ocular hypertension; Prostaglandin analogue; Timolol; Travoprost

Indexed keywords

ACETAZOLAMIDE; ADRENALIN; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIHYPERTENSIVE AGENT; APRACLONIDINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BIMATOPROST; BRIMONIDINE; BRINZOLAMIDE; CARBACHOL; CARBONATE DEHYDRATASE INHIBITOR; CARTEOLOL; DIPIVEFRINE; DORZOLAMIDE; ECOTHIOPATE IODIDE; LATANOPROST; LEVOBUNOLOL; METHAZOLAMIDE; METIPRANOLOL; MIOTIC AGENT; PILOCARPINE; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; PROSTANOID RECEPTOR; TIMOLOL; TRAVOPROST; UNINDEXED DRUG; UNOPROSTONE ISOPROPYL ESTER; CLOPROSTENOL; DRUG DERIVATIVE; PROSTAGLANDIN F2ALPHA RECEPTOR; PROSTAGLANDIN RECEPTOR;

AQUEOUS HUMOR OUTFLOW; ARTICLE; BRADYCARDIA; BRONCHOSPASM; CENTRAL NERVOUS SYSTEM DISEASE; CIRCADIAN RHYTHM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STABILITY; DRUG STRUCTURE; EDEMA; EYE DISEASE; FREEZING; GLAUCOMA; HIGH TEMPERATURE; HUMAN; HYPEREMIA; HYPERPIGMENTATION; HYPOTENSION; INTRAOCULAR PRESSURE; LIGHT EXPOSURE; LOW TEMPERATURE; NEGRO; NONHUMAN; PHASE 2 CLINICAL TRIAL; RACE DIFFERENCE; RECEPTOR AFFINITY; THAWING; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECT; INTRAOCULAR HYPERTENSION; RACE; REVIEW;

ADRENERGIC BETA-ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS; CLOPROSTENOL; COMPARATIVE STUDY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; OCULAR HYPERTENSION; RACIAL STOCKS; RECEPTORS, PROSTAGLANDIN; SUPPORT, NON-U.S. GOV'T; TIMOLOL; CONTINENTAL POPULATION GROUPS; HUMANS;

EID: 0035987743     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.3.7.965     Document Type: Article

References (73)

1. Neuronal death in glaucoma
2. Number of people with glaucoma worldwide
3. Optic nerve damage in human glaucoma. III. Quantitative correlation of nerve fiber loss and visual field defect in glaucoma, ischemic neuropathy, papilledema, and toxic neuropathy
4. Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey
5. Models of glaucoma prevalence and incidence in the United States
6. Genetic risk of primary open-angle glaucoma. Population-based familial aggregation study
7. Identification of a gene that causes glaucoma
8. Adult-onset primary open-angle glaucoma caused by mutations in optineurin
9. Is there an association between migraine headache and open-angle glaucoma?
10. Glaucoma and vasospasm
11. Blindness and visual impairment in an American urban population. The Baltimore Eye Survey
12. Prevalence of glaucoma. The Beaver Dam Eye Study
13. Correlation between intraocular pressure control and progressive glaucomatous damage in primary open-angle glaucoma
14. Visual field prognosis in advanced glaucoma
15. Visual prognosis in advanced glaucoma
16. Topical timolol administration reduces the incidence of glaucomatous damage in ocular hypertensive individuals. A randomized, double-masked, long-term, clinical trial
17. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between of intraocular pressure and visual field deterioration
18. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures
19. Target pressure
20. Intraocular pressure and glaucoma
21. Target pressure - Glaucomatologists' holey grail
22. The effects of sleep on circulating catecholamines and aqueous flow in human subjects
23. Twenty-four hour pattern of intraocular pressure in the aging population
24. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma
25. Racial differences in the cause-specific prevalence of blindness in East Baltimore
26. The Advanced Glaucoma Intervention Study (AGIS): 4. Comparison of treatment outcomes within race. Seven-year results
27. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension
28. Compliance with ocular therapy
29. Compliance in patients prescribed eyedrops for glaucoma
30. Overview of patient compliance with medication dosing: A literature review
31. Once-daily administration of phenobarbital in adults. Clinical efficacy and benefit
32. Once-daily versus twice-daily dosing of theophylline. A decision analysis approach to evaluating theophylline blood levels and compliance
33. Frequency of contraindications to topical beta-blockers in a glaucoma population
34. Short-term escape and long-term drift. The dissipation effects of the beta-adrenergic blocking agents
35. Comparative data for all counties
36. Comparison of the ocular beta-blockers
37. A double-masked comparison of betaxolol versus timolol in the treatment of open-angle glaucoma
38. Effects of apraclonidine on aqueous humour dynamics in human eyes
39. Effect of chronic apraclonidine treatment on intraocular pressure in advanced glaucoma
40. Effects of brimonidine on aqueous humour dynamics in human eyes
41. Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension
42. A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure
43. Changing therapeutic paradigms in glaucoma management
44. A double-masked, randomized, 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol
45. A triple-masked, primary therapy study of the efficacy and safety of BID and TID-dosed brinzolamide 1% compared to TID-dosed dorzolamide 2% and BID-dosed timolol 0.5%
46. The long-term safety and efficacy of brinzolamide (AZOPT), a new topical carbonic anhydrase inhibitor, in patients with open-angle glaucoma and ocular hypertension
47. Phase III latanoprost studies in Scandinavia, the United Kingdom, and the United States
48. Effects on intraocular pressure and side effects of 0.005% latanoprost once daily, evening or morning. A comparison with timolol
49. Clinical dose-regimen studies with latanoprost, a new ocular hypotensive PGF2A analogue
50. The additive intraocular pressure-lowering effect of latanoprost in combined therapy with other ocular hypotensive agents
51. Effect of temperature and light on the stability of latanoprost and its clinical relevance
52. A double-masked, randomized comparison of the efficacy and safety of unoprostone with timolol and betaxolol in patients with primary open-angle glaucoma including pseudoexfoliation glaucoma or ocular hypertension
53. A comparison of intraocular pressure-lowering effect of prostaglandin f2-alpha analogues, latanoprost and unoprostone isopropyl
54. Six-month comparison of bimatoprost q.d. and b.i.d. with timolol b.i.d. in patients with elevated intraocular pressure
55. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension
56. Mechanism of action of bimatoprost (Lumigan)
57. The ocular effects of prostaglandins and the therapeutic potential of a new PGF2α analog, PhXA41 (latanoprost), for glaucoma management
58. Preclinical efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist
59. Travoprost antiglaucoma prostaglandin fp agonist, AL-6221, Travatan™
60. Studies on the characterization of prostanoid receptors: A proposed classification
61. 3 and FP prostaglandin receptor binding sites in bovine corpus luteum: Characterization and correlation with functional data
62. Inhibitors of the arachidonic acid cascade in the management of ocular inflammation
63. Comparison of the effects of prostaglandins and their esters on blood-aqueous barrier integrity and intraocular pressure in rabbits
64. FP prostaglandin receptors mediating inositol phosphates generation and calcium mobilization in Swiss 3T3 cells: A pharmacological study
65. Pharmacological characterization of an FP prostaglandin receptor on rat vascular smooth muscle cells (A7R5) coupled to phosphoinositide turnover and intracellular calcium mobilization
66. Safety and pharmacokinetics of travoprost, a potent prostaglandin F (FP) receptor agonist, in patients with renal and hepatic impairment
67. Dose-response evaluation of travoprost ophthalmic solution (Travatan), a new topical ocular prostaglandin, in patients with open-angle glaucoma and ocular hypertension
68. Travoprost: A new once-daily dosed prostaglandin for the reduction of elevated intraocular pressure
69. Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated IOP: A six-month, masked, multicenter trial
70. Comparison of topical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension
71. Evaluation of travoprost as adjunctive therapy in patients with uncontrolled intraocular pressure while using timolol 0.5%
72. Travatan administration results in effective diurnal reduction in intraocular pressure over 36 hours and lower pressures up to 3.5 days without further dosing